Τρίτη 14 Ιουνίου 2022

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial

alexandrossfakianakis shared this article with you from Inoreader

1-s2.0-S1473309922X00066-cov150h.gif

Publication date: Available online 13 June 2022

Source: The Lancet Infectious Diseases

Author(s): Sean R Bennett, James M McCarty, Roshan Ramanathan, Jason Mendy, Jason S Richardson, Jonathan Smith, Jeff Alexander, Julie E Ledgerwood, Paul-André de Lame, Sarah Royalty Tredo, Kelly L Warfield, Lisa Bedell

View on Web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου